13d (edited) • Regulatory Updates
PPA Regulatory Tracker: April 2026 Inaugural Edition
Twelve peptides removed from FDA Category 2. PCAC public meeting July 23–24, 2026. State boards continue to fill in around the federal floor.
This is the first edition of PPA's Monthly Regulatory Currency Tracker. Every month, this digest reports what the FDA, DEA, state pharmacy boards, and major clinical bodies are saying about peptide therapy, with primary sources cited for every item. Educational only. Not legal or medical advice.
The April 2026 drop is the largest single regulatory event since the September 2024 Category 2 nominator withdrawals. Review it before your next prescription. Verify with your compounding pharmacy. Document the regulatory status in the chart note.
——
What's in this edition
• Q1 2026 catch-up. January through March 2026 in three pages, for prescribers joining mid-year.
• Section 1. FDA 503A bulks list. Twelve peptides removed from Category 2 on April 15, 2026; PCAC public meeting July 23–24, 2026.
• Section 2. FDA enforcement. Thirty warning letters to telehealth GLP-1 marketers (March 3); Gram Peptides Research Use Only warning letter (March 31); 503A and 503B exemption reminder (April 1).
• Section 3. DEA scheduling and telemedicine. No new federal peptide scheduling in April. Controlled-substance telemedicine flexibility extended through December 31, 2026.
• Section 4. State pharmacy boards. California, Texas, Florida, New York, Arizona, plus the next five top states. California's June 2025 Essentially a Copy rule remains the active enforcement vector.
• Section 5. Clinical guidance. A4M Peptide Therapy Certification curriculum continues. AACE, AAPS, and ISPRM positions tracked.
• Section 6. Telehealth. Federal posture, state posture, what's coming.
• Section 7. Notable research. Retatrutide TRIUMPH-4 (December 2025). NEJM SURMOUNT-5 tirzepatide vs. semaglutide head-to-head (2025).
• Per-peptide regulatory status table. All 28 peptides covered in the PPA curriculum, in one snapshot.
• Upcoming dockets and dates to watch.
• Operational considerations checklist and chart-note documentation template.
• Change log and sources.
——
The single most consequential April 2026 event
On April 15, 2026, the FDA removed twelve peptide bulk drug substances from Category 2 of the 503A interim bulks list and scheduled the Pharmacy Compounding Advisory Committee (PCAC) to review seven of them on July 23 and 24, 2026.
Removal from Category 2 is not the same as inclusion in Category 1. Until PCAC votes and the FDA issues a final action, these substances occupy regulatory gray space. A 503A pharmacy may continue compounding under patient-specific prescriptions, subject to state law and the pharmacy's own risk posture, but the supply line is not guaranteed past the July meeting outcomes.
Verify status with your compounding pharmacy before every refill during this period. Document patient counseling about possible mid-protocol supply changes.
——
Three operational items for the week
- Pull up the per-peptide status table in the PDF. Patients on BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, or Epitalon are now in the post-April-2026 PCAC-pending period. Note the regulatory status in the next chart entry for each of those patients.
- 2. Audit telehealth platform language. If you are listed on or accept referrals from a third-party telehealth GLP-1 site, review their advertising for any wording that implies equivalence to FDA-approved branded products. The FDA's March 3, 2026 warning letter wave focused on exactly this language.
- 3. Bookmark the PDF. Each edition is published the first Wednesday of the month. Subscribers receive the fresh edition by email the morning it drops.
——
Download the full edition
The full April 2026 PDF (print-ready, with the per-peptide table and the dates-to-watch section) is attached to this post and lives in the Regulatory Tracker folder of the PPA Skool community.
Companion files in the same folder:
• Tracker_2026-04_April_Inaugural.docx — Word source for prescribers who want to copy chart-note language directly.
• Tracker_Template.docx — reusable monthly template for future editions.
• Sources_Bibliography.md — every URL cited in the April edition, organized by section.
——
Editorial framing
This tracker reports what regulators and clinical guidance bodies are saying. It does not direct prescribing action. Each item names WHAT changed, WHO it affects, WHERE to verify, and WHAT prescribers may want to consider with their compliance counsel.
Off-label prescribing, regulatory uncertainty, and supply-chain risk are clinical decisions that belong to the prescriber and the prescriber's legal advisor. The Peptide Prescriber Academy provides the source material; the prescriber retains sole responsibility for clinical judgment and regulatory compliance.
——
Discussion prompt
Comment on this post with the regulatory question weighing on your practice most this quarter. The most-discussed items get answered in the May 2026 edition.
——
Next edition
The May 2026 edition publishes Wednesday, June 3, 2026, covering whatever moves between now and then, plus the build-up to the July PCAC meeting.
— Peptide Prescriber Academy
0
0 comments
PPA Regulatory Tracker: April 2026 Inaugural Edition
powered by
Suggested communities
Powered by